Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Pacific Clinical Trial: OGX-427 in MCRPC
NCT01681433Phase 2Terminated
- Start
- Dec 2012
- Primary completion
- Jun 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of apatorsen in metastatic castration-resistant prostate cancer (mCRPC). Started Dec 2012; status: terminated.
02
Drugs
apatorsen
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01681433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01681433.